BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 27439908)

  • 1. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
    Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
    Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
    Han Y; Xie W; Song DG; Powell DJ
    J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
    Kim M; Pyo S; Kang CH; Lee CO; Lee HK; Choi SU; Park CH
    PLoS One; 2018; 13(6):e0198347. PubMed ID: 29874279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T-cell therapy for triple-negative breast cancer: Where we are.
    Xie Y; Hu Y; Zhou N; Yao C; Wu L; Liu L; Chen F
    Cancer Lett; 2020 Oct; 491():121-131. PubMed ID: 32795486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate Receptor α-Targeted
    Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
    Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
    Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
    Front Immunol; 2020; 11():573823. PubMed ID: 33072116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers.
    Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C
    Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer.
    Zhao Z; Li Y; Liu W; Li X
    Biomed Res Int; 2020; 2020():4795171. PubMed ID: 31998790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
    Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
    Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice.
    Pfeifer R; Al Rawashdeh W; Brauner J; Martinez-Osuna M; Lock D; Herbel C; Eckardt D; Assenmacher M; Bosio A; Hardt OT; Johnston ICD
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Stüber T; Monjezi R; Wallstabe L; Kühnemundt J; Nietzer SL; Dandekar G; Wöckel A; Einsele H; Wischhusen J; Hudecek M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.